Tech Company Financing Transactions
Illexcor Therapeutics Funding Round
Zynext Ventures participated in a funding round for Illexcor Therapeutics. The financing round was announced on 3/13/2025.
Transaction Overview
Company Name
Announced On
3/13/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Richmond, VA Undisclosed
USA
Richmond, VA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our mission is to discover, develop and deliver next generation therapies that improve the lives and outcomes of people living with hematologic diseases. We are focused on advancing next generation oral therapies for the treatment of sickle cell disease. Our goal is to develop best-in-class oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits. Our lead drug ILX002 is the first of its kind that binds to Hemoglobin S and directly blocks polymerization and sickling.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Fleischman
Browse more venture capital transactions:
Prev: 3/13/2025: Zero Point Motion venture capital transaction
Next: 3/13/2025: Rangsons Aerospace venture capital transaction
Share this article
About Our VC Transactions Data
We report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs